TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02945813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850mg PO BID; 48 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage Radiotherapy SRT
Description: SRT 35 x 2Gy; 7 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Radiotherapy SRT
Description: SRT 35 x 2Gy; 7 weeks
Study: NCT03605914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco
Description: The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
Study: NCT03773146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery Airtime Incentive
Description: An incentive given in the form of airtime
Study: NCT02668510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: placebo injection of normal saline immediately following shockwave therapy
Study: NCT03374059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Study: NCT03057275

Intervention type: DEVICE
Intervention: Abdominal fetal/maternal monitoring
Description: A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device

Intervention type: DEVICE
Intervention: Abdominal fetal/maternal monitoring
Description: A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
Study: NCT02617654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Treatment with liraglutide for 52 weeks
Study: NCT03374059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life modification
Study: NCT02617654

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for liraglutide
Description: Placebo for liraglutide. Treatment once daily for 52 weeks
Study: NCT04676035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
Description: * Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27
Study: NCT01714999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bursectomy
Description: Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bursal reconstruction
Description: The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
Study: NCT02416895

Intervention type: OTHER
Intervention: In vivo immunity model
Description: A measure of in vivo immune function.
Study: NCT01195480

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta
Description: All patients will be treated at the same total dose level of 2 x 10\^8/m2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta
Description: All patients will be treated at the same total dose level of 2 x 10\^8/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated donor-derived Lymphoblastoid Cell Line
Description: The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in \> 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10\^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion.
Study: NCT03339440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hearts & Parks
Description: The Hearts \& Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
Study: NCT02038257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Dressing
Description: Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
Study: NCT01195480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated donor-derived Lymphoblastoid Cell Line
Description: The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in \> 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10\^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion.
Study: NCT01810497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of ear bandage
Description: Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of ear bandage
Description: Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
Study: NCT01678625

Intervention type: DEVICE
Intervention: Train-of-four ratio calculation (T4-EMG)
Description: TOF ratios will be compared between the EMG and AMG groups

Intervention type: DEVICE
Intervention: Train-of-four ratio calculation (T4-EMG)
Description: TOF ratios will be compared between the EMG and AMG groups
Study: NCT03382106

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Description: Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Description: Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pulse wave velocity
Description: Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Carotid artery compliance and stiffness
Description: An echocardiogram is done by using a probe placed on the skin.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Carotid artery compliance and stiffness
Description: An echocardiogram is done by using a probe placed on the skin.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Carotid artery compliance and stiffness
Description: An echocardiogram is done by using a probe placed on the skin.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pressure wave reflection
Description: Carotid pulse measurement taken using a tonometer probe

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pressure wave reflection
Description: Carotid pulse measurement taken using a tonometer probe
Study: NCT00414804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision SCS
Description: Precision Spinal Cord Stimulation (SCS) Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Blocks and PT
Description: Pain therapy utilizing Nerve Blocks with Physical Therapy
Study: NCT01185795

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardioviva™ yogurt
Description: L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
Study: NCT02038257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline Impregnated Gauze
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
Study: NCT03382639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: TAK-831 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: TAK-831 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: TAK-831 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Luvadaxistat placebo-matching tablets.
Study: NCT02038257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline Impregnated Gauze
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide Laser
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
Study: NCT01528722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% 20ml administered intraperitoneal

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: sodium chloride 0.9% solution
Study: NCT03739346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell, show, do technique
Description: The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
Study: NCT02133612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel; cisplatin
Description: The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
Study: NCT02275156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study: NCT03107494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gala Airway Treatment System
Description: The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
Study: NCT00002812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV
Study: NCT01708473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advil
Description: One (1) tablet 800 mg Advil one hour prior to treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lortab
Description: One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
Study: NCT00002812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT01708473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT00002812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study: NCT04081246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral modified en bloc resection of bladder tumour
Description: Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
Study: NCT01072175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
Study: NCT00002812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study: NCT04384120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
Study: NCT00002812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given IV
Study: NCT02058849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beetroot
Description: 10g Beetroot powder mixed with 4-8 oz.
Study: NCT00002812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02058849

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02968095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Craving Program
Description: Text messages targeting cravings delivered 2-3 times per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Manual Plus Control Texts
Description: Self-help manual plus motivational text messages delivered 2-3 times per day.
Study: NCT02083406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 prototype formulation 1
Study: NCT00002812

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00293618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Risk Presentation in the operating room
Description: Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Feedback about the physician's personal performance on prevention of PONV